TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02365740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric emptying test
Description: gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: gastric emptying test
Description: gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gut hormones determination
Description: blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: gut hormones determination
Description: blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
Study: NCT01519882

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day.
Study: NCT04218877

Intervention type: OTHER
Description: There will be no intervention, only observation

Intervention type: OTHER
Description: There will be no intervention, only observation

Intervention type: OTHER
Description: There will be no intervention, only observation
Study: NCT02365740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: 7 days Continuous Glucose Monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin single bolus
Description: pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
Study: NCT01009359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
Study: NCT04305496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study: NCT04267952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention program developed according to planned behavior theory
Description: The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classical hand hygiene education
Description: expression of hand hygiene with verbal presentation method in a 40-minute lecture
Study: NCT00940316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given intravenously 6mg/kg every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given intravenously 6mg/kg every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given intravenously 6mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally 150mg daily
Study: NCT02365740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin double-wave bolus
Description: pre-prandial insulin fractioned into a double-wave bolus
Study: NCT04303247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted CAR-T cells
Description: The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Study: NCT00453453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide given orally in the emergency department
Study: NCT00137267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time limited case management
Description: This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
Study: NCT04770701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ahah Drug
Description: - Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahah Placebo
Description: - Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Study: NCT00934752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel-Coated Balloon
Description: Percutaneous transluminal coronary angioplasty (PCTA)
Study: NCT06331806

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of myocardial fibrosis
Description: echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
Study: NCT01650610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training executive functions tasks
Description: The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
Study: NCT00940316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally 150mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally 150mg daily
Study: NCT02197806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Study: NCT02210832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: financial incentives
Description: financial incentives provided contingent on biochemically confirmed smoking abstinence
Study: NCT01806064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Axitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Study: NCT04377477

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single fraction whole lung radiotherapy
Description: Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
Study: NCT02258230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
Study: NCT00940316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
Study: NCT00645892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
Study: NCT03647670

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
Study: NCT02258230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
Study: NCT01330966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
Study: NCT03647670

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
Study: NCT02052193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Measurement of toxicity related to UV exposure
Study: NCT00690092

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spherule-derived coccidioidin
Description: 1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spherule-derived coccidioidin
Description: 1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
Study: NCT01722292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study: NCT00690092

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spherule-derived coccidioidin
Description: 1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
Study: NCT02299986

Intervention type: OTHER
Intervention: Ultrasound measurement
Description: Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
Study: NCT03477227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short stocking
Description: Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual stocking
Description: Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
Study: NCT01722292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study: NCT01585623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazol
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Pharmaceutical form:solution~Route of administration: oral
Study: NCT01090258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamilton ventilator (G5 modify to S1) Automated settings
Description: Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton ventilator (G5) protocolized settings
Description: Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
Study: NCT01049490

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S-OIV H1N1 vaccine
Description: Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
Study: NCT02052193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Measurement of toxicity related to UV exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Measurement of toxicity related to UV exposure
Study: NCT01722292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered IV
Study: NCT01722292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01614171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone
Description: growth hormone treatment for 6 months (daily, weight based)
Study: NCT00431210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific adoptive T-cells immunotherapy
Description: Given intravenously on Day 1 and Day 14
Study: NCT03439670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of 2.0 mg/kg/day for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral administration of 0.75 mg/kg/day for 24 weeks.
Study: NCT00771797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose flavanoids
Description: flavanoid rich cocoa 2 times daily over 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose flavanoids
Description: treatment with flavanoid-low cocoa two times daily over 60 days
Study: NCT04670393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FertyBiotic Woman Plus
Description: 4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mcg folic acid
Study: NCT01676519

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study: NCT02052193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Measurement of toxicity related to UV exposure
Study: NCT04521101

Intervention type: OTHER
Group type: OTHER
Intervention: VAST Course
Description: Educational course to teach non-technical skills
Study: NCT03885583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural block
Description: thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
Study: NCT05588739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
Study: NCT02332889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine (autologous dendritic cells)
Description: Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Hiltonol
Description: Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
Study: NCT00715182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT01634165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Administered subcutaneously
Study: NCT01272492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Use
Description: Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
Study: NCT00243412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Minimum of 1 mg/day oral (or folinic acid 5 mg/week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Minimum of 1 mg/day oral (or folinic acid 5 mg/week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
Study: NCT01634165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Administered subcutaneously
Study: NCT04753021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressively increasing training load
Study: NCT04167865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Orthosis, mobilization, strengthening, posture and segmental breathing exercises